VistaGen to Participate in Upcoming June Investor Conferences
VistaGen will present at upcoming
Format: Fireside Chat
Date and Time:
Location:
Format: Company Presentation
Date and Time:
Location:
The live and archived webcasts of VistaGen’s fireside chat and presentation will be accessible through the News/Events page of the Investors section of the Company’s website at www.VistaGen.com.
About VistaGen
VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing first-in-class therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the olfactory to limbic amygdala circuit without systemic uptake or direct activity on CNS neurons in the brain. VistaGen’s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005062/en/
Investors
Vice President, Investor Relations,
Phone: (650) 577-3617
Email: mflather@vistagen.com
Media
SKDK
Email: nhitchings@skdknick.com
Source: